Netarsudil
Glaucoma · Rx
RxGlaucomaGlaucoma Rho
| Strength | 0.02% |
|---|---|
| Typical quantity | 2.5 mL bottle (brand only, no generic) |
| Cash cost / month | High · ~$100-350 |
| Drug class | Rho kinase (ROCK) inhibitor |
| Mechanism of action | Inhibits Rho-associated kinase and the norepinephrine transporter; relaxes the trabecular meshwork to increase conventional outflow, lowers episcleral venous pressure, and reduces aqueous production. Targets the diseased outflow pathway directly. |
| Indication / reason for use | Open-angle glaucoma and ocular hypertension. |
| Usual adult dosing | 1 drop in the affected eye(s) once daily in the evening. |
| Preservative | BAK 0.015% |
| Contact lenses | Remove lenses; reinsert after 15 minutes. |
| Common / important adverse effects | Conjunctival hyperemia (very common, ~50%), conjunctival hemorrhages (small, benign, recurrent), cornea verticillata (reversible whorl keratopathy, usually visually insignificant), instillation site pain, reticular corneal epithelial edema (less common). |
| Contraindications & cautions | Hypersensitivity. |
| Pregnancy / lactation | No human data. |
| Pregnancy category (older labels) | No letter category on the current label. From DailyMed labels, checked Nov 2026. |
| Trade names | Rhopressa |
| Practice notes | Hyperemia and the cosmetic subconjunctival hemorrhages drive most discontinuations, set expectations. Efficacy is preserved at low baseline IOP, which is useful in normal-tension glaucoma. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.